PMID: 32690643DOI: 10.1128/aac.01450-20Jul 22, 2020Paper
Safety, Tolerability, and Pharmacokinetics of a Novel Oral Amphotericin B Formulation (iCo-019) following Single-Dose Administration to Healthy Human Subjects: an Alternative Approach to Parenteral Amphotericin B Administration.
Antimicrobial Agents and Chemotherapy
Peter HnikKishor M Wasan
Abstract
This study evaluated the safety, tolerability, and pharmacokinetics of a novel oral amphotericin B (AmB) formulation (iCo-019) following single doses to healthy humans. The data from this study suggest that iCo-019 has a long circulation time and systemic exposure without the associated gastrointestinal, liver, and kidney toxicity associated with AmB. This novel oral AmB formulation can serve as a new treatment strategy to overcome the limitations of the use of parenterally administered AmB products.
References
Nov 22, 1993·Drug and Therapeutics Bulletin
Feb 28, 1997·Chemistry and Physics of Lipids·J Barwicz, P Tancrède
Jul 18, 2002·Antimicrobial Agents and Chemotherapy·G DelmasD S Perlin
May 19, 2006·International Journal of Antimicrobial Agents·Michael Kleinberg
Dec 7, 2007·Advanced Drug Delivery Reviews·Kristina Sachs-BarrableKishor M Wasan
Jul 5, 2008·International Journal of Pharmaceutics·Raquel EspadaJuan J Torrado
Feb 25, 2009·International Journal of Pharmaceutics·Ellen K WasanKishor M Wasan
Apr 29, 2009·The Journal of Antimicrobial Chemotherapy·Pavel GershkovichKishor M Wasan
Jun 24, 2009·The Journal of Infectious Diseases·Kishor M WasanSheila J Thornton
Dec 15, 2010·PLoS Neglected Tropical Diseases·Ellen K WasanKishor M Wasan
Mar 12, 2011·The Journal of Antimicrobial Chemotherapy·Vijay Kumar PrajapatiShyam Sundar
Aug 10, 2011·Lipids in Health and Disease·Olena SivakKishor M Wasan
Dec 14, 2011·The Journal of Infectious Diseases·Vijay Kumar PrajapatiShyam Sundar
Mar 1, 2012·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Fady IbrahimKishor M Wasan
Oct 24, 2012·AAPS PharmSciTech·Zhiwen YangChuanbin Wu
Apr 30, 2013·International Journal of Biological Macromolecules·Kuldeep SinghVikas Rana
Jun 4, 2013·International Journal of Pharmaceutics·Acarília Eduardo SilvaE Sócrates T Egito
Mar 8, 2014·Drug Delivery·Rishikesh KumarPradeep Das
Dec 6, 2014·TheScientificWorldJournal·Saurabh BhatiaTanmoy Bera
Jan 7, 2015·Molecular Pharmaceutics·Dolores R SerranoIjeoma F Uchegbu
Dec 15, 2015·International Journal of Nanomedicine·Ying-Chen ChenMing-Thau Sheu
Dec 30, 2015·Drug Delivery and Translational Research·Manisha B ChaudhariVandana B Patravale
Feb 6, 2017·Drug Delivery·Mahasen A RadwanBenjamin Horrocks
May 17, 2017·Clinical Pharmacokinetics·Kevinkumar A KansagraKinjal Barot
Oct 3, 2017·Journal of Liposome Research·Gerard M Jensen
Dec 28, 2017·Drug Delivery and Translational Research·Heba A MohamedAmr El-Hag Ali
Feb 8, 2018·Colloids and Surfaces. B, Biointerfaces·A R RichterR C M de Paula
Aug 23, 2018·Pharmaceutical Development and Technology·Janet Sui Ling TanNashiru Billa
Mar 1, 2019·Pharmaceutics·Grace CuddihyKishor M Wasan
May 30, 2019·MBio·R LuP R Williamson
Mar 13, 2020·Current Pharmaceutical Design·Kishor Wasan
❮ Previous
Next ❯
Citations
Aug 21, 2020·Antimicrobial Agents and Chemotherapy·Kishor M WasanPeter Hnik
❮ Previous
Next ❯
Related Concepts
Related Feeds
CRISPR Screens in Drug Resistance
CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.
Related Papers
Drug Delivery
Min LiuZhiwen Yang
Antimicrobial Agents and Chemotherapy
J A Sánchez-BruneteJ J Torrado
Acta biochimica Polonica
M BaginskiEdward Borowski
Mini Reviews in Medicinal Chemistry
J Golenser, A Domb
Antimicrobial Agents and Chemotherapy
Elisabeth J RuijgrokArnold G Vulto